Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3b study of the duration of effect of Bimatoprost SR in open-angle glaucoma or ocular hypertension
2022-502380-37-00Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 13
01
Overview
Phase 3, open-label, single-arm trial of bimatoprost in open-angle glaucoma (OAG) and ocular hypertension, sponsored by AbbVie Inc. Primary endpoint: Duration of effect of Bimatoprost SR. Started Sep 2023; status: completed.
02
Drugs
bimatoprost
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on 2022-502380-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502380-37-00.